Trials / Unknown
UnknownNCT05863260
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
Tislelizumab (Anti-PD-1) Combined With Definitive Chemoradiotherapy in Recurrent Cervical Cancer (PILOT-2020-511): a Single-arm, Phase 2 Trial
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase ii and observational clinical study
Detailed description
Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase ii and observational clinical study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Treatment Group | Treatment Group |
Timeline
- Start date
- 2020-11-09
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
- First posted
- 2023-05-18
- Last updated
- 2023-05-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05863260. Inclusion in this directory is not an endorsement.